Drug Trial Radar · NCT07077512
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 15, 2025
Primary completion
Jan 15, 2027
Study completion Jul 15, 2027
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fifth Affiliated Hospital of Guangzhou Medical University; Guangzhou Overseas Chinese Hospital,Guangdong
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
Conditions
- Large B Cell Diffuse Lymphoma
- Mantle Cell Lymphoma (MCL)
- Follicular Lymphoma ( FL)
Interventions
Autoleucel (Relmacabtagene Autoleucel)Drug
Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodepletion (fludarabine + cyclophosphamide).
Sintilimab (PD-1 inhibitor)Drug
Patients will receive intravenous Sintilimab (200 mg every 3 weeks) starting on Day 28 after reinfusion, continuing until disease progression or intolerable toxicity, with a maximum duration of 1 year.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The complete response rate (CRR) at 3 monthsTime frame: Up to 3 months after Relmacabtagene Autoleucel infusion
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Universitiy Cancer Center
Guangzhou, China · Recruiting
Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, China · Not yet recruiting
Guangzhou overseas Chinese hospital
Guangzhou, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.